Dual-speci®city protein tyrosine phosphatases are a burgeoning family of enzymes, some of which, the MKPs, are implicated in the regulation of mitogenactivated protein (MAP) kinases. MKPs have been shown to reverse the activation of the MAP kinases by hydrolyzing phosphothreonine and phosphotyrosine residues present in the substrates. Here we describe the characterization of a novel member of the MKP family, MKP5. The MKP5 gene, which maps to human chromosome 1q32, is expressed tissue-speci®cally as two transcripts of approximately 3.4 and 2.4 kb in human liver and skeletal muscle. When expressed in mammalian cells, MKP5 blocks the enzymatic activation of MAP kinases with the selectivity p38&JNK/ SAPK44ERK. Immunoprecipitation of endogenous MAP kinases by the catalytically inactive transfected MKP5 demonstrates that it preferentially binds to the p38 and JNK/SAPK kinases. These ®ndings suggest that the selectivity of this phosphatase may be determined at least in part at the level of substrate binding.
Introduction
Members of the Mitogen-Activated Protein (MAP) kinase family play a crucial role in the activation of signaling cascades in response to a diverse range of extracellular stimuli, including growth and differentiation factors as well as pro-in¯ammatory cytokines and cellular stresses (reviewed in Marshall, 1995; Kyriakis and Avruch, 1996; Cohen, 1997; Ip and Davis, 1998) . To date, three distinct classes of MAP kinases have been identi®ed which dier in their substrate speci®city and regulation. These subgroups comprise of the extracellular signal-regulated kinases (ERK), the cJun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and the p38/RK/CSBP kinases (reviewed in Cano and Mahadevan, 1995) .
Several signal transduction pathways utilizing the ERKs have been characterized (reviewed in Robinson and Cobb, 1997) . Sustained activation of the ERKs leads to neuronal dierentiation in PC12 cells, while it has been linked to mitogenic stimulation in ®broblasts (Cowley et al., 1994; Pages et al., 1993; Mansour et al., 1994) . The roles of the JNK/SAPK and p38 kinases, which are activated by exposure to stress stimuli (reviewed in Kyriakis and Avruch, 1996; Ip and Davis, 1998) have been addressed utilizing speci®c chemical kinase inhibitors, or expression of dominant negative mutant forms of the kinases, or their upstream regulators. These studies indicate that these MAP kinases are involved in pathways leading to the generation of in¯ammatory cytokines and may play a role in apoptotic cell death (Cohen, 1997; Ichijo et al., 1997; Yang et al., 1997; Xia et al., 1995; Verheij et al., 1996) . However, the precise role of these kinases during apoptosis remains controversial.
Activation of the MAP kinases is achieved by the phosphorylation of both threonine and tyrosine residues present in the signature sequence TXY of the kinase domain VIII (Marshall, 1995; Cohen, 1997; Cano and Mahadevan, 1995) . Several upstream activators have been isolated and characterized, which are speci®c for each class of MAP kinase. Conversely, these kinases are inactivated by the dephosphorylation of these residues, which is carried out by members of the expanding group of dual-speci®city phosphatases. To date, nine distinct MAP kinase phosphatases have been identi®ed (reviewed in Keyse, 1995 Keyse, , 1998 .
Unlike the upstream kinases, the majority of these phosphatases do not display such clear cut selectivity for their targets. A characteristic example is that of the prototypic member of the family, MKP-1 (Keyse and Emslie, 1992; Charles et al., 1992) , which was originally identi®ed as an ERK-speci®c phosphatase (Noguchi et al., 1993; Sun et al., 1993 Sun et al., , 1994 . However, it has since been demonstrated that MKP-1 also catalyzes the dephosphorylation of both JNK/SAPK and p38 (Chu et al., 1996; Hirsch and Stork, 1997; Franklin and Kraft, 1997) . Nevertheless, recent in vitro studies suggest that MKP-3/PYST1 (Muda et al., 1996a; Mourey et al., 1996; Groom et al., 1996) and M3/6/ hVH-5 (Theodosiou et al., 1996; Martell et al., 1995) are highly selective in inactivating either ERK, or JNK/SAPK and p38 MAP kinases, respectively (Groom et al., 1996; Muda et al., 1996b Muda et al., , 1998 . The N-terminal non-catalytic domain of MKP-3 appears to be responsible for binding the ERK2 MAP kinase, thus directing the speci®city of this phosphatase Camps et al., 1998) .
Here we describe the identi®cation and characterization of a novel member of the family of dual-speci®city phosphatases, MKP5. The predicted amino acid sequence contains both the extended active site signature motif and two N-terminal Cdc25 homology domains, characteristic of all other members of this family. When expressed in mammalian cells, MKP5
inactivates both p38 and JNK/SAPK MAP kinases. This substrate selectivity together with its restricted tissue distribution pattern suggests a distinct function for MKP5, from previously characterized members of this family.
Results and discussion

Identi®cation of a novel human dual-speci®city phosphatase
The dual-speci®city phosphatases display a high degree of sequence similarity within their catalytic domain. In order to identify new members of this family, we performed BLAST searches of the expressed sequence tag data base (dbEST) for cDNA fragments containing this conserved region. We identi®ed a human sequence (GENBANK accession number AA056633) which had signi®cant sequence similarity with other members of this family. This clone (IMAGE Consortium ID 509569) was obtained and fully sequenced. The insert of 1937 bp, encompassed the complete open reading frame of a novel gene which we have designated MKP5. The putative ATG initiation codon is followed by an open reading frame of 1446 nucleotides. Close to the 3' end of the cDNA is a poly(A) addition sequence (AATAAA) immediately preceeding a poly(A) tract ( Figure 1a) .
The cDNA encodes an open reading frame of 482 amino acids ( Figure 1a ) with a predicted molecular weight of approximately 52 kDa. Comparison of this sequence with the GENBANK database revealed high sequence similarity with other members of the family of dual-speci®city phosphatases. In particular, the MKP5 protein contains (amino acids 407 ± 424) the extended active site signature motif (HCXAGXSRSX-TXXXAY[I/L]M, where X is any amino acid) conserved in all dual-speci®city phosphatases (Keyse, 1995; Martell et al., 1995) . Furthermore, the N-terminal region of MKP5 also displays regions of sequence similarity with Cdc25, the cell cycle regulatory protein. These regions known as the CH2 domains (cdc25 homology) are A B Figure 1 Nucleotide and predicted amino acid sequence of human MKP5 cDNA and alignment with other dual-speci®city phosphatases. (a) Amino acids are indicated using the single-letter code. Nucleotides and amino acids are numbered on the right, starting at the ®rst nucleotide of the cloned cDNA and at the ®rst predicted methionine, respectively. The in-frame stop codon is denoted by an asterisk. The extended active-site signature motif conserved in dual-speci®city phosphatases is double underlined. The two cdc25 homology domains (CH2 domains) are single underlined. The human MAP kinase phosphatases sequence used are: hVH-5/M3/6, GENBANK accession number U29193; MKP-4, accession number Y08302; PYST1, accession number X93920; PYST2, accession number X93921; CL100/MKP-1, accession number X68277; hVH-2, accession number U21108; hVH-3/B23, accession number U16996; PAC-1, accession number L11329. (b) Phylogenetic analysis of MAP Kinase Phosphatases. All-againstall comparisons of phosphatase domains were performed using Darwin suite of programs running on the Computational Biochemistry Research Group Server at EidgenoÈ ssische Technische Hochschule, ZuÈ rich (http://cbrg.inf.ethz.ch/welcome.html). The multiple alignment was obtained by adjusting the relative positions of the sequences to maximize the similarity scores. These scores were then used by the TreeGen component of the system to generate trees from the distance data (Suhai, 1994) . The alignment was reformatted using the Prettyplot program of GCG (Genetics Computer Group, Wisconsin Package Version 9.1, Madison, USA). The numbers are arbitrary and indicate distances also characteristic of the members of this family and it has been suggested that they confer substrate speci®city or function as interaction points with other proteins (Keyse and Ginsburg, 1993) . In addition to these well established areas of conservation among the members of the MAP kinase phosphatases, there is a third region of similarity, recently identi®ed, and referred to as the cyclin B homology motif (Martell et al., 1998) . This motif is located 26 amino acids carboxy-terminal to the AY(L/I)M at the end of the active site sequence and has a consensus of FxxQLLQxE (amino acids 451 ± 459). The role of this motif in the MAP kinase phosphatases has yet to be established, although it has been suggested that it could serve as an interaction point with cell cycle proteins (Martell et al., 1998) . Moreover, the MKP5 protein appears to contain another conserved motif known as the Dbox (Jacobs et al., 1999) . Alignment of DNAbinding proteins containing such motifs has resulted in the following consensus:
, which corresponds to the sequence REGKEPLVL (amino acid 261 ± 269) in MKP5. This motif has been suggested to function as a docking site that mediates binding to ERK and JNK MAP kinases. The dual-speci®city phosphatase M3/6 (Theodosiou et al., 1996) also contains this consensus whereas MKP1/CL100 and MKP-2 (Keyse and Emslie, 1992; Misra-Press et al., 1995) contain a more highly conserved motif (FXFP) which is speci®c for mediating binding to ERK (Jacobs et al., 1999) . Interestingly, in all the above cases, the MAPK docking motifs are located C-terminally to the catalytic domains of the phosphatases as compared to MKP5, where the motif is located Nterminally. Whether its position in the protein aects its accessibility has yet to be determined.
The highest degree of similarity was observed between the catalytic C-terminal regions of these proteins as described previously . Using the GAP alignment program (GCG, Wisconsin, USA), MKP5 was most similar to hVH-5/M3/6 (43% amino acid identity in the phosphatase domain), PYST2/MKP-X (49%), PYST1/MKP-3/rVH6 (50%) and MKP-4 (49%). However, phylogenetic analysis of the catalytic domains of the dual-speci®city phosphatases, revealed two major clusters of sequences ( Figure  1b) . In one cluster, members (CL100, hVH-2, B23 and PAC-1) share the common characteristic of being localized exclusively in the nucleus of the cell (Keyse and Emslie, 1992; Guan and Butch, 1995; Ishibashi et al., 1994; Rohan et al., 1993) . Sequences belonging to the second cluster (PYST-1, PYST-2 and MKP-4), are localized predominantly in the cytoplasm of cells, and also appear to be more speci®c for ERK than other MAP kinases (Groom et al., 1996; Muda et al., 1997) . From this analysis, MKP5 appears not to be part of these existing clusters and may be the prototype of a new class of MAP kinase phosphatases.
MKP5 is tissue-speci®cally expressed
To establish which tissues express the MKP5 gene we performed northern blot analysis using as a probe the MKP5 cDNA encompassing the entire ORF. This revealed that the MKP5 mRNA is expressed in a restricted manner displaying a major band of approximately 3.4 kb, predominantly in human liver Markers placed at odds ratio of 10 : 1 or higher are in plain type. These mapping data can be accessed using the WorldWide Web server of the Whitehead Institute (http://www.genome.wi.mit.edu/ cgi-bin/contig/phys_map) but also in skeletal muscle where it appears to be expressed at lower levels ( Figure 2) . A higher mobility and fainter band (approximately 2.4 kb) was also detected in those tissues. CL100 and hVH-2 are also expressed in the liver (Keyse and Emslie, 1992; Guan and Butch, 1995) . However, both are found in a number of other tissues, including lung, placenta, pancreas and heart, at similar or higher levels. The tissue distribution of the MKP5 RNA is quite dierent to other members of the family, suggesting a distinct function for this phosphatase. Analysis of the expressed sequence tag database (dbest) suggests that MKP5 is also expressed in other human tissues such as the retina, macrophages, the colon, foetal heart liver and spleen, infant brain, pregnant uterus and an ovarian tumour (data not shown).
Chromosomal location of the MKP5 gene
The chromosomal location of the gene for MKP5 was determined by the identi®cation of a previously mapped sequence tagged site (STS) within the MKP5 cDNA (STS WI-16074) (Schuler et al., 1996) , and localizes to human chromosome 1q32, between the framework markers WI-4922 and WI-6955 (Figure 3 ). These mapping data can be accessed using the World Wide Web server of the Whitehead Institute (http:// www.genome.wi.mit.edu/cgi-bin/contig/phys_map).
Many de-regulated protein tyrosine kinases have been found to be encoded by oncogenes leading to the suggestion that tyrosine phosphatases might function Figure 4 Subcellular localization of MKP5. COS-7 cells were transfected with pMT-SM-Myc-MKP5 (wild type and Cys408-Ser mutant) which encodes MKP5 with a C-terminal c-myc epitope recognized by the 9E10 monoclonal antibody, using LipofectA-MINE. Cells were ®xed, permeabilized, and expressed protein detected by immuno¯uorescence using monoclonal antibody 9E10 with FITC-conjugated donkey anti-mouse antibody. The 9E10 antibody does not recognize the epitope in endogenous c-myc and is speci®c for the expressed MKP5. Both wild type (a) and (b) and Cys408-Ser Myc-MKP5 (c) and (d) localize to both the nucleus and the cytoplasm Figure 5 MKP5 inhibits p44 ERK1, p54 SAPKb and p38 MAP kinases in intact cells. COS-7 cells were transfected with either p44 HA-ERK1, p54 HA-SAPKb or HA-p38 MAP kinase (1.0 mg plasmid) together with 0.05, 0.1, 0.25, 0.5 or 1.0 mg of Myc-MKP5 plasmid as indicated. Plasmid concentrations were maintained constant using pMT-SM III vector. Following culture for 40 h, cells were incubated for 2 h in serum-free medium and then stimulated with either 10 nM EGF (p44 HA-ERK1) for 10 min, 10 mg/ml anisomycin (p54 HA-SAPKb) for 30 min, or 0.5 mM H 2 O 2 (HA-p38) for 30 min. Following cell lysis, MAP kinases were immunoprecipitated using anti-HA epitope speci®c monoclonal antibody prebound to protein A-sepharose beads. Immune complex assays were then performed using MBP (p44 ERK1), GST-c-Jun (1-79) (p54 SAPKb) or GST-ATF-2 (p38) as substrates in the presence of [g- as tumour suppressor genes. Inactivation of the genes encoding tyrosine phosphatases may contribute to the aberrant phosphorylation associated with certain neoplastic conditions. The chromosomal localization of all dual-speci®city phosphatases identi®ed thus far has now been established (Theodosiou et al., 1996; Muda et al., 1997; Noguchi et al., 1993; Martell et al., 1994; Yi et al., 1995; Smith et al., 1997; Nesbit et al., 1997 ) and a number of these genes map to chromosomal regions frequently altered in human cancers. Martell et al., 1994; Yi et al., 1995; Smith et al., 1997; Nesbit et al., 1997) . It has been shown that the MKP-1 phosphatase is overexpressed during the early phases of human epithelial carcinogenesis and could therefore act as a marker for a wide range of tumours (Loda et al., 1996; Magi-Galluzi et al., 1997; Yokoyama et al., 1997) . In contrast, analysis of the levels of PYST1/MKP-3 in pancreatic cancer cell lines revealed reduced expression of this phosphatase in some of these cell lines suggesting a role of PYST1 in pancreatic carcinogenesis (Furukawa et al., 1998) . Deletions of human chromosome 1q32, the region to which MKP5 localizes, have been reported in renal collecting duct carcinoma (CDC) and some breast tumours (Steiner et al., 1996; Benitez et al., 1997) . However, we do not know whether loss of MKP5 is involved in the pathogenesis of these tumours.
Subcellular localization of MKP5
We have studied the subcellular localization of myctagged MKP5 following expression in COS-7 cells. MKP5 protein, both wild type and catalytically inactive (Cys 408 to Ser), is detectable in both the nucleus and the cytoplasm of the majority of stained cells, with strongest cytosolic staining around the nuclear membrane ( Figure  4a ± d) . The subcellular localization of MKP5 diers from that of the other dual speci®city phosphatases. MKP-1/ CL100, PAC-1, hVH-2/MKP-2/TYP-1 and hVH-3/B23 are localized entirely within the nucleus (Rohan et al., 1993; Guan and Butch, 1995; Kwak and Dixon, 1995; Brondello et al., 1995) , MKP-3/PYST1 is entirely cytoplasmic (Muda et al., 1996a; Groom et al., 1996) , MKP-4 is mainly cytoplasmic with some punctate staining in the nucleus , while hVH-5/M3/6 is cytosolic or nuclear depending on cell type (Theodosiou et al., 1996) . Two N-terminal charged clusters of amino acids, RRAR-(15)-RAR, have been identi®ed in hVH-3/B23 (Kwak and Dixon, 1995; Ishibashi et al., 1994) . Similar clusters are present in the amino acid sequences of MKP-1/CL100 (RRRAK-(14)-RGR) (Keyse and Emslie, 1992) , hVH-2/MKP-2/TYP-1 (RRRAK-(15)-RAR) (King et al., 1995; Misra-Press et al., 1995; Guan and Butch, 1995) , PAC-1 (RRRAR-(16)-RTR) (Rohan et al., 1993) , and MKP-4 (RRLRR-(30)-RRRR) . Although not clear bipartite nuclear localization sequences (Dingwall and Laskey, 1991) , these sequences may contribute to the subcellular localization of these phosphatases. However, no similar sequence is present in MKP5 (Figure 1a ).
MAP kinase inactivation by MKP5
To determine the substrate speci®city of MKP5 in intact cells, HA-tagged MAP kinases p44-ERK1, p54-SAPKb, and p38 were co-transfected together with Myc-tagged MKP5 in COS-7 cells. To gain an impression of the relative eectiveness of MKP5 to inactivate each MAP kinase, cells were transfected using a range of MKP5 plasmid concentrations (0.05 ± 1 mg/well) as described previously (Figure 5a ).
Using this approach, MKP5 showed some activity towards all three MAP kinases at high plasmid concentrations, but showed moderate selectivity for p54-SAPKb and p38 at lower concentrations, when compared with p44-ERK1. H 2 O 2 -stimulated p38 activation was inhibited by *55% when cells were (Figure 5a ). Under such conditions MKP5 expression could not be detected by Western blot analysis (Figure 5c ). This level of MKP5 expression also inhibited anisomycin-stimulated p54-SAPKb by *25% but had very little eect on EGF-stimulated p44-ERK1 (Figure 5a ). Inhibition of p38 and p54-SAPKb activation was increased to *70% following transfection with 0.25 mg of MKP5 expression plasmid, while activation of p44-ERK1 was inhibited by only * 25% (Figure 5a ).
These studies suggest that MKP5 is signi®cantly more eective towards p38 and SAPK family isoforms than towards ERK family members (p38&JNK44 ERK). Importantly, these results would suggest that MKP5 selectivity is similar to that of M3/6, which is also more speci®c towards the stress-activated kinases (JNK/SAPK&p38444ERK) (Muda et al., 1996b) . It would also appear that the enzymatic speci®city of these two members (MKP5 and M3/6), is quite dierent from MKP-4 (ERK4p38=JNK/SAPK) , MKP-3 (ERK44JNK/SAPK &p38) (Muda et al., 1996a; Groom et al., 1996) , MKP-2 (ERK=JNK/SAPK4p38) (Chu et al., 1996) and PAC-1 (ERK=p384JNK/SAPK) (Chu et al., 1996) .
Binding of MKP5 to endogenous MAP kinases
To verify and extend the above results, we carried out transient transfections of COS-7 cells with either the wild type or the catalytically inactive mutated form (Cys 408 to Ser) of the MKP5 cDNA clone, and looked at the ability of the transfected phosphatases to interact with the endogenous MAP kinases. Transfected cells were starved of serum, prior to stimulation of endogenous MAPKs with EGF, arsenite or anisomycin. The MKP5 mutant form is able to bind p38 MAP kinase as observed by coimmunoprecipitation of p38 with Myc-tagged MKP5 (Figure 6a ). In contrast, the catalytically active form of MKP5 does not co-immunoprecipitate this MAP kinase (Figure 6a ), which probably indicates that upon binding, the phosphatase dephosphorylates its substrate and subsequently releases it. These results are consistent with the pattern observed in Figure 6b . Total protein lysates of the transfected cells were resolved on a polyacrylamide gel and immunoblotted with the phosphotyrosine-speci®c p38 antibody. The phosphorylated form of this MAP kinase was only detected in the lysates of cells transfected with the catalytically inactive form of MKP5, whereas no trace was seen in those transfected with the wild type form of the phosphatase, presumably because of dephosphorylation by the wild type MKP5.
The same approach was used to evaluate whether the MKP5 Cys 408 to Ser mutant form binds to and`pulls down' the JNK/SAPK (Figure 6d ) or ERK2 MAP kinases (data not shown). Immunodetection with the anti-ERK2 antibody showed no binding of this phosphatase to the endogenous ERK2, which is consistent with the substrate-speci®city data presented above. However, both catalytically active and inactive forms of MKP5 were able to bind and pull-down endogenous JNK/SAPK (Figure 6d ). In this assay, the catalytically inactive mutant of the M3/6 phosphatase was used as a positive control (Theodosiou et al., 1996) . Immunoblotting with an anti-phospho JNK antibody revealed that the catalytically active form of MKP5 completely dephosphorylates the JNK1/2 isoforms whereas the mutated form does not (Figure 6e ). An explanation for this observation could be that MKP5 binds JNK/SAPK through a domain other than the active site (a candidate could be the docking site that mediates binding to ERK and JNK MAP kinases). This association could be independent of the activation state of JNK. Recent studies suggest that the N-terminal noncatalytic domain of MKP-3 is responsible for tight binding to its substrates p44-ERK1 and p42-ERK2 . Moreover, MKP-3 is activated by binding to puri®ed ERK2 and this activation is independent of protein kinase activity (Camps et al., 1998) . Whether this is a common mechanism for the regulation of other members of the MAP kinase phosphatase family remains to be determined. However, it seems plausible that the sequence diversity among the N-termini of these phosphatases ensures speci®c binding to a distinct set of target substrates.
In summary, we have identi®ed a novel dual-speci®city phosphatase which we have designated MKP5. This phosphatase is structurally similar to other members of the family, containing an extended active-site signature motif as well as two N-terminal Cdc25 homology domains. However, MKP5 appears to have a rather distinct tissue distribution, being expressed predominantly in liver as well as skeletal muscle. The subcellular localization of MKP5 also diers from that of other members of the family. It has been postulated that the localization of these phosphatases is re¯ective of their substrate speci®city. Our data suggest that p38 may be a substrate for MKP5. p38, like MKP5, has been shown to be present in both the nuclear and the cytoplasmic compartments of the cell , and could thus be accessible to MKP5. Activation of p38 occurs in the nucleus and is followed by movement to the cytoplasm in a complex with its substrate, phosphorylated MAPKAP kinase-2 (Ben- Levy et al., 1998) .
We have demonstrated by co-transfections that this phosphatase inactivates MAP kinases with the selectivity p38&JNK/SAPK44ERK. This enzymatic speci®city is similar to that observed with M3/6 in this type of assay (Muda et al., 1996b and is quite dierent to that of MKP-3. Interestingly, MKP5 and M3/6 are the only members of the family identi®ed thus far, that contain a D-box motif (Jacobs et al., 1999) , which could mediate binding to JNK. Further work is required to elucidate the molecular basis of the substrate selectivity of the MAP kinase phosphatases.
Materials and methods
Reagents
Restriction enzymes were purchased from New England Biolabs Inc., LipofectAMINE from GIBCO BRL and Taq DNA polymerase from Perkin-Elmer. Protein G-Sepharose 4B fast¯ow beads, murine EGF, sodium m-arsenite and anisomycin were purchased from Sigma. Anti-Myc monoclonal antibody 9E10 was provided by the antibody unit of Institute of Cancer Research. The anti-p38 MAPK, phosphospeci®c p38 MAPK and anti-SAPK/JNK polyclonal antibodies were obtained from New England Biolabs, the antiactive JNK polyclonal antibody was purchased from Promega, while the horseradish peroxidase conjugated donkey anti-rabbit IgG and goat anti-mouse IgG were from Pierce. The FITC-conjugated donkey anti-mouse secondary antibody was purchased from Jackson Immuno Research Laboratories Inc.
Mammalian Expression Plasmids
MKP5 was subcloned into pMT-SM III, a modi®ed version of the eukaryotic expression vector pMT-SM (Muda et al., 1996a; Schaap et al., 1993) , in which the 9E10 Myc epitope coding sequence is incorporated, in-frame, into the multiple cloning site. Primers TTAGGTACCTGT-CTTGAGTTCTT-CTTGAATTGC (nucleotides 74 ± 106) and CCATCTAGA-CCACGCCCATCAGC (nucleotides 1579 ± 1545) were used to amplify MKP5 ORF from human breast cDNA (the underlined nucleotides correspond to the engineered Asp718 and XbaI sites). After digestion, the cDNA was subcloned into the Asp718 and XbaI sites of the expression vector pMT-SM III. To generate the enzymatically inactive MKP5-Myc-tagged protein, the essential catalytic Cys 408 was changed to Ser by site-directed mutagenesis. PCR amplification was carried out using the following combinations of oligonucleotides: T3 and GCTTCTCATCCACAGC-G (nucleotides 1333 ± 1360); T7 and CACCC-CAGCCTGGCTGTGGATGAGAAGC (same as above). The mutant MKP5 clone was completely sequenced and subcloned into the modi®ed pMTSM III mammalian expression vector using the restriction enzymes NotI and EcoRI.
Northern blot analysis
A mouse multiple-tissue Northern blot (Clontech) was hybridized according to manufacturer's instructions. The membrane was washed to a ®nal stringency of 0.16SSC, 0.1% SDS at 558C. The blot was visualized by autoradiography after exposure for 4 days at 7708C. Hybridization with GAPDH was used as a loading control.
Cell culture and transfection
COS-7 cells were grown at 10% CO 2 in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% foetal calf serum. These were plated at a density of 1.25610 5 cells per well in 6-well plates and transfected with 1 mg of plasmid/well using 6 mg of LipofectAMINE. Following 6 h exposure to LipofectAMINE, the cells were washed and grown for 24 h prior to starvation by incubation in serum-free medium for 18 h. Cells were then stimulated for 20 min with EGF (10 nM), arsenite (500 mM), anisomycin (10 mg/ml) or left unstimulated.
For co-transfection experiments, COS-7 cells were grown and transfected as described previously (Muda et al., 1996b using the following plasmid concentrations: 1.0 mg of pcDNA1-HA-p44-ERK1, pMT2T-HA-p54-SAPKb or pcDNA3-HA-p38 together with 0.05, 0.1, 0.25, 0.5 or 1.0 mg of pMT-SM-Myc-MKP5. Following transfection, cells were grown for 40 h before starvation by incubation in serum-free medium for 2 h. Cells were then treated with EGF (10 nM), anisomycin (10 mg/ml), or H 2 O 2 (0.5 mM) at 378C for 10 ± 30 min (Muda et al., 1996b .
Immunoprecipitation, immune complex kinase assays and immunodetection
For co-immunoprecipitation of endogenous kinases, cells were washed twice with ice-cold phosphate-buered saline and lysed in ice-cold lysis buer (Groom et al., 1996) . Proteins bound to the transfected phosphatases were coimmunoprecipitated by the addition of protein G-Sepharose beads, prebound to anti-myc monoclonal antibody (9E10) at a ratio of 1 mg antibody per 1 ml beads, and incubation with shaking for 2 h at 48C. The immunoprecipitates were washed twice in lysis buer and four times in 50 mM Tris-HCl (pH 7.5). The samples were resolved by SDS ± PAGE. Endogenous MAP kinases were detected using the polyclonal anti-p38 MAPK, anti-SAPK/JNK and anti-ERK2 antibodies. Immunoprecipitation of HA-tagged MAP kinases and Myc-tagged MKP5, immune complex kinase assays and Western blotting were all performed as described previously (Muda et al., 1996a .
For immuno¯uorescence, cells were ®xed 48 h posttransfection with 4% paraformaldehyde in PBS, permeabilized, and incubated with monoclonal antibody 9E10 for 1 h at room temperature. Cells were then washed with PBS and incubated for 1 h with FITC-conjugated donkey anti-mouse secondary antibody. Visualization was with a confocal imaging system (BIORAD 1024).
